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Abstract
Cornelia de Lange syndrome (CdLS) is amultisystemgenetic disorder with distinct
facies, growth failure, intellectual disability, distal limb anomalies, gastrointestinal
and neurological disease. Mutations in NIPBL, encoding a cohesin regulatory
protein, account for >80% of cases with typical facies. Mutations in the
core cohesin complex proteins, encoded by the SMC1A, SMC3 and RAD21
genes, together account for ̃5% of subjects, often with atypical CdLS features.
Recently, we identified mutations in the X-linked gene HDAC8 as the cause
of a small number of CdLS cases. Here, we report a cohort of 38 individuals
with an emerging spectrum of features caused by HDAC8 mutations. For
several individuals, the diagnosis of CdLS was not considered prior to genomic
testing. Most mutations identified are missense and de novo. Many cases are
heterozygous females, each with marked skewing of X-inactivation in peripheral
blood DNA.Wealso identified eight hemizygous males who are more severely
affec...
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Cornelia de Lange syndrome (CdLS) is amultisystem genetic disorder with distinct facies, growth failure, intel-
lectual disability, distal limb anomalies, gastrointestinal and neurological disease. Mutations inNIPBL, encod-
ing a cohesin regulatory protein, account for >80% of cases with typical facies. Mutations in the core cohesin
complex proteins, encoded by the SMC1A, SMC3 and RAD21 genes, together account for ∼5% of subjects,
often with atypical CdLS features. Recently, we identified mutations in the X-linked gene HDAC8 as the cause
of a small number of CdLS cases. Here, we report a cohort of 38 individuals with an emerging spectrum of fea-
tures caused by HDAC8mutations. For several individuals, the diagnosis of CdLS was not considered prior to
genomic testing.Most mutations identified are missense and de novo. Many cases are heterozygous females,
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eachwithmarkedskewingofX-inactivation inperipheral bloodDNA.Wealso identifiedeight hemizygousmales
who aremore severely affected. The craniofacial appearance caused byHDAC8mutations overlaps that of typ-
ical CdLS but often displays delayed anterior fontanelle closure, ocular hypertelorism, hooding of the eyelids, a
broader nose and dental anomalies, which may be useful discriminating features. HDAC8 encodes the lysine
deacetylase for the cohesin subunit SMC3 and analysis of the functional consequences of the missense muta-
tions indicates that all cause a loss of enzymatic function. These data demonstrate that loss-of-function muta-
tions in HDAC8 cause a range of overlapping human developmental phenotypes, including a phenotypically
distinct subgroup of CdLS.
INTRODUCTION
Cornelia de Lange syndrome and cohesin
Cornelia de Lange syndrome (CdLS; or Brachmann-de Lange
syndrome, OMIM 122740, 300590, 610759 and 614701) is a
genetically heterogeneous disorder with congenital malforma-
tions that include characteristic facial features, growth retard-
ation, intellectual disability and limb anomalies. Typical CdLS
is caused by de novo, heterozygous mutations in NIPBL (1–7),
and recent data have demonstrated that as many as 20% of indi-
viduals may have mosaic mutations that are not readily detect-
able in blood (8). NIPBL encodes the human ortholog of the
Drosophila Nipped-B (9) and yeast Scc2 proteins, key compo-
nents of sister chromatid cohesion (10). NIPBL is required for
the chromosomal loading of the cohesin complex (11,12),
which comprises four highly conserved subunits: SMC1,
SMC3, RAD21 (hSCC1) and STAG (SCC3/SA) (13). Approxi-
mately 5% of patients with CdLS, usually those with milder con-
genital anomalies or atypical facial features, have mutations in
the human SMC1A gene (14,15). One patient has been reported
with a mutation in the SMC3 gene (16) and several have been
noted with mutations in RAD21 (17). However, 10–20% of
patients with typical CdLS have no identified etiology. In add-
ition, a high number of individuals with atypical CdLS or an
overlapping phenotype have no identified cause.
Acetylation of SMC3 and the role of HDAC8
The acetylation of SMC3 at key lysine residues is required to es-
tablish the cohesiveness of chromatin-loaded cohesin during
S-phase (18–20). In addition, SMC3 is rapidly deacetylated
during mitosis (19–21) and was noted in yeast to be regulated
by the class I deacetylase Hos1 (22–24). We recently identified
HDAC8 as the vertebrate SMC3 deacetylase and demonstrated
its role in recycling cohesin from one cell cycle to the next
(25). Furthermore, we identifiedHDAC8mutations in six indivi-
duals with typical CdLS or an overlapping phenotype.
To investigate and fully characterize the range of clinical fea-
tures in patients with HDAC8 mutations, we screened an inter-
nationally assembled cohort of 586 patients with typical CdLS
and overlapping clinical presentations who had no known mo-
lecular etiology. Here we report on a range of mutations, includ-
ing chromosomal aberrations, nonsense and missense mutations
that disrupt HDAC8 and clarify the clinical spectrum of features
in individuals with these mutations. This study demonstrates the
range of phenotypes caused by HDAC8 mutations in an emer-
ging era of genomic/exomic sequencing, since seven subjects
herein were identified by genomic studies (array and exome se-
quencing) independent of a CdLS diagnosis. This work serves to
emphasize the range of features seen in individuals withHDAC8
mutations and underscores their distinctness from typical CdLS.
Furthermore, it portends the likelihood that additional subjects
will be identified by NGS approaches.
RESULTS
We recently identified HDAC8 as the vertebrate deacetylase re-
sponsible for deacetylating cohesin to facilitate its recycling
(25) and identified mutations in a small number of subjects from
a cohort of children with CdLS. Also recently, a family with an
X-linked pattern of obesity and mental retardation in males was
noted to have an intronic HDAC8 mutation that segregates with
the phenotype (26). To further clarify the clinical consequences
of HDAC8 mutations in human developmental disorders, we
assembled a large international cohort of individuals with CdLS
and overlapping phenotypes and screened for mutations.
Identification of HDAC8 mutations in a large cohort
of patients
We assessed 586 individuals with CdLS and overlapping pheno-
types for whom screening for mutations in NIPBL, SMC1A and,
in most cases, SMC3 (see Materials and Methods) was negative.
Among this cohort, we identified 25 probands, three affected
family members and three unaffected mothers with mutations
in HDAC8, revealing a cause in 4% of probands. In addition,
two children were ascertained by discovery of de novo HDAC8
microdeletions and five as a result of identifying a de novo
HDAC8 mutation using clinical exome sequencing, all these
latter cases prior to considering the diagnosis of CdLS. In
total, including the six previously reported individuals (25),
this includes six different chromosomal microdeletions or
microduplications, three nonsense mutations, one splice site
and 16 different missense mutations (Fig. 1). Of the mutations,
23 occurred de novo in the affected child, six were maternally
inherited (in four families) and in seven the inheritance could
not be fully confirmed.
HDAC8 mutations in CdLS cause loss of enzyme activity
To obtain independent data regarding the effect and severity of
these mutations on protein function, we mapped mutations
onto the previously reported crystal structure of HDAC8
(27,30) (Fig. 1B) and expressed the wild type and each of the
2890 Human Molecular Genetics, 2014, Vol. 23, No. 11
mutated forms of HDAC8 in Escherichia coli. We purified
each and assayed deacetylase activity using a commercially
available HDAC8 assay (31) (Fig. 1C; Supplementary Material,
Table S1).
Wild-type HDAC8 requires a single zinc ion for the hydrolysis
of N6-acetyllysine side chains in acetylated protein substrates
such as SMC3 (blue sphere in Fig. 1B). The side chains of
D178, H180 and D267 coordinate to the zinc ion and play a crit-
ical role in stabilizing the active site structure and modulating the
chemistry of the zinc ion for catalysis (32). X-ray crystal struc-
tures of inactive HDAC8 mutants complexed with peptide sub-
strates reveal extended regions of the protein surface capable
of interacting with protein substrates, including a portion of
the L2 loop (light blue in Fig. 1B) that exhibits moderate flexibil-
ity in the binding of substrates and inhibitors (27,30,33,34). A
catalytically important internal channel leading to possible exit
channels for the acetate hydrolysis product has been identified
in modeling and mutagenesis studies (green and purple tubes
in Fig. 1B) (28,29). This channel may facilitate catalysis when
HDAC8 is bound to large protein substrates by providing a
"back door" exit for the small product without first requiring dis-
sociation of the HDAC8-substrate complex. Inspection of muta-
tion sites mapped onto the HDCA8 structure reveals that most
appear capable of compromising molecular features required
for optimal catalytic function.
Based on structural location and enzymatic activity, muta-
tions are classified into four groups. The first group of mutations
(H180R, G304R, H71Y andDK239-Y240N) completely inacti-
vate the enzyme. The H180R mutation destroys the binding site
of the catalytically obligatory zinc ion. The G304R mutation
introduces a large positively charged residue near the active
site that might destabilize the protein structure and/or block sub-
strate binding. The H71Y substitution disrupts hydrogen bonds
with the backbone NH group of N156 and the backbone carbonyl
groups of K145 and K146, which may destabilize the L2 loop and
adjacent residues that accommodate substrate binding. Finally,
Figure 1. Mutations in HDAC8. (A) Copy number abnormalities that disrupt the HDAC8 locus. Localization of deletions (red) and duplications (blue) on Xq13 are
indicated by chromosome band and position (hg19). Gene locations are indicated in blue with gene names.HDAC8 is indicated in bold. (B) Localization of HDAC8
missense mutations on the crystal structure (PDB accession code 2V5W (27)). Mutated residues are in red and labeled. The acetylated substrate is in gray and the active
site zinc ion (Zn) is in dark blue. The light blue portion indicates the L2 substrate-binding loop. Green and purple tubes indicate the catalytically important main and
branch exit channels, respectively, for the acetate hydrolysis product (28,29). (C) HDAC8 mutations disrupt deacetylase activity. Bar graphs demonstrate the effect of
HDAC8 mutations on deacetylase relative activity relative to the wild-type enzyme activity (specific activities are noted in Supplementary Material, Table S1). All
assays were performed in triplicate. Error bars indicate standard deviation. Enzymatic activity for all mutations is significantly less than wild type (P , 0.05) using a
two-tailed unpaired t-test. Single letter amino acids are used for mutation notation to correlate with residues in (B and C). (D) Conservation of mutations in HDAC8.
Alignment of HDAC8 and related deacetylases from 10 species, as indicated on the left. Residues identical to the human residue in a majority of species at each position
are in bold, in dark gray and a black border. Those that are similar are shaded in lighter gray, without a border. Each mutated human residue is indicated at the top, with a
yellow box surrounding the aligned residues. Note the conservation through yeast for all residues in which a missense mutation causes a complete loss of function.
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the positively charged amino group of K239 makes an electro-
static interaction with D355 and donates a hydrogen bond to
the backbone carbonyl group of N357. While the side chain of
adjacent residue Y240 does not make any hydrogen bond inter-
actions with protein residues, it is close to the active site. The de-
letion of K239 and the simultaneous Y240N mutation suggests
they perturb the protein scaffold in the vicinity of the active
site to abolish catalytic activity.
The second mutation group, comprised of G117E and C153F, is
characterized by residual enzyme activity less than 10% of that
observed for the wild-type enzyme. The larger, negatively
charged glutamate side chain of G117E would be oriented
toward solvent. However, it could sterically perturb the conform-
ation of the adjacentK60-A62 polypeptide segment, todestabilize
the nearby L2 loop. C153 is located only 10 A˚ away from the
catalytically obligatory zinc ion, and it is also close to H142 and
H143, residues that are known to be involved in catalysis
(30,32). The substitution by a larger hydrophobic phenylalanine
is likely to dramatically remodel the active site and thus impair
catalysis.
A third group of mutations (T311M, I19S, G320R, A188T,
D233G, D237Y and I243N) exhibit 10–50% residual activity
compared with the wild-type enzyme. The T311M mutation may
perturb the putative internal channel for product acetate dissoci-
ation, and the I19S may perturb one of the possible acetate exit
channels that branch away from the internal channel. Addition-
ally, the T311M and G320R mutations may compromise the
active site structure, since the helix containing these residues
(helix H2) buttresses the b-sheet comprising one wall of the
active site. The T311 hydroxyl group also donates a hydrogen
bond to the backbone carbonyl group of N307, and disruption
of this hydrogen bond by the T311M mutation would destabilize
the protein. The guanidinium side chain in the G320R mutation
would occupy a cleft on the surface of the protein, but it is diffi-
cult to explain how this particular substitution might influence
the active site structure. A188 is in a hydrophobic environment,
surrounded by F70, V159, L163, V185 and F189; mutation to a
larger, partially hydrophilic residue might subtly affect packing
interactions. D233 is located on the protein surface, but its carb-
oxylate group accepts a salt-linked hydrogen bond from the side
chain of K202. The deletion of the carboxylate group in the
D233G mutant disrupts this interaction; being moderately
close to the active site, this mutation might cause some subtle
structural changes that compromise catalysis. The carboxylate
side chain of D237 accepts hydrogen bonds from the side
chain hydroxyl group and the backbone NH group of T280,
and D237 is moderately close to the active site. Mutation of
D237 to a less polar residue in the D237Y mutant probably
causes a structural rearrangement that propagates through to
the active site. Finally, while I243 is a partially conserved
residue among the HDAC isozymes, analysis of the HDAC8
structure does not suggest any particular reason for the loss of ac-
tivity resulting from this mutation.
A fourth group of mutations (P91L and H334R) exhibit rela-
tively minor but significant losses of catalytic activity (residual
activities .50% compared with the wild-type enzyme). H334
is located on the protein surface far from the active site, and
P91L is in the portion of the L2 loop that is most distant from
the active site.
The varying loss of activity of these mutations also correlates
with the amino acid conservation at each site (Fig. 1D). Each of
the substitution mutations that result in complete ablation of ac-
tivity (H71Y, H180R and G304R) alters a residue that is identical
from humans through yeast. Mutations with minor or intermedi-
ate losses of activity largely reside in residues that are less
conserved in non-vertebrates, although nearly all mutations
occur in residues that are nearly identical in vertebrates, consist-
ent with the overall high conservation of sequence in vertebrate
HDAC8 homologs.
HDAC8mutations are associated with severely skewed
X-inactivation
To assess theHDAC8mutations effect on RNA, we evaluated ex-
pression in cell lines available for several of the probands. We
noted that for a male subject (case ID CDL426P), with a hemizy-
gous missense mutation, the mutant transcript was detectable, as
expected for this X-linked gene. However, for available lympho-
blastoid cell lines from females (CDL016P, CDL209P,
CDL248P, CDL317P and CDL603P) that harbored heterozygous
missense mutations (Table 1), we were only able to detect the
wild-type allele, even in the presence of the nonsense-mediated
decay inhibitor cycloheximide. Since blood cell lines freely mix
and wouldbeexpected todemonstratebiallelic expression, this in-
ability to detect the mutant allele suggested selection for expres-
sion of the normal allele in these cell lines or in peripheral blood
prior to their establishment. We then analyzed the allelic expres-
sion in a fibroblast cell line from the female probands CDL016P
and CDL248P, the only two subjects for whom both lymphoblas-
toid and fibroblast cell lines were available. We reasoned that the
line derived from a small skin biopsy had a better possibility of
being clonallyderivedandwould be less subject to selection. Con-
sistent with this possibility, these cells expressed only the mutant
allele, also supporting the likelihood of selection within the per-
ipheral blood (25) (Table 1).
Because lymphoblastoid and fibroblast cell lines are available
for only a small subset of patients, we analyzed for skewing of
X-inactivation as a marker of HDAC8 allele selection in the
peripheral blood. To accomplish this, we utilized a well-
characterized assay that measures the methylation status of a
microsatellite repeat in the 5′UTR of the androgen receptor (AR)
of the inactivated X chromosome (35). For 23 heterozygous
females for whom peripheral blood genomic DNA or cell lines
were available, 20 were skewed .95:5, one was skewed
between 95:5 and 70:30, one showed no skewing and two were un-
informative due homozygous polymorphisms at the testing locus.
Of note, the three samples that were skewed,95:5 were all from
girls aged,4years when the sample was obtained,whichsupports
the hypothesis that selection of the normal allele occurs after birth.
Clinical features of individuals with HDAC8mutations
CdLS is noted for growth, cognitive delays, limb anomalies and
distinctive facial features. Of the 35 affected individuals identi-
fied in this work with mutations inHDAC8, all have clinical fea-
tures that overlap those seen in CdLS, although few subjects are
fully consistent with that diagnosis. Figure 2 demonstrates facial
and limb findings, Supplementary Material, Table S2 details the
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clinical features for each individual and Table 2 demonstrates
the summary of clinical findings in this cohort. The range of phe-
notypes was consistent with that seen for an X-linked disorder,
with males being more affected. In multiplex families, we
observed apparently unaffected carrier females. This sex-
weighted effect is illustrated by the differences in average
height, weight and head circumference between the two sexes
in affected individuals (Table 3).
In this cohort of affected individuals, many features are quite
similar to those observed in typical CdLS. These include non-
specific findings such as postnatal growth retardation (28%),
microcephaly (29%), hearing loss (59%), gastroesophageal reflux
(67%), feeding difficulties (86%), cardiac defects (36%), genito-
urinary anomalies (44%) and intellectual disabilities (100%).
Many also display craniofacial features suggestive of CdLS,
including brachycephaly (70%), arched eyebrows (88%),
synophrys (90%), long eyelashes (45%), depressed nasal bridge
(45%), anteversion of the nares (76%), long philtrum (57%),
downturned corners of the mouth (57%), small widely spaced
teeth (61%), micrognathia (59%) and cleft palate without cleft
lip (18%). Other findings suggestive of CdLS include cutis mar-
morata (18%), hirsutism (65%), small hands (96%) and feet
(89%), toe syndactyly (44%), verbal performance that is worse
than motor performance and development of behavioral problems
with age. Only one patient demonstrates a major limb anomaly.
However, several features are unique in these patients that are
not seen in typical CdLS. These include delayed fontanelle
closure (50%), ocular hypertelorism (47%) and/or telecanthus
(64%), hooding or redundant overfolded skin of the upper
eyelids (46%), a broad or bulbous nasal tip (66%), a prominent
gap between the central incisors (50%), dental anomalies
(50%, including oligodontia and fused incisors), nevus flam-
meus (58%), mosaic skin pigmentation (25%), limb length
discrepancies in the absence of major malformations (n ¼ 5)
and happy or friendly personalities as younger children (50%).
Finally, several features are absent in this cohort that are com-
monly seen in typical CdLS. For example, the growth tends to be
less disrupted with lower frequency of postnatal growth retard-
ation (28%) and microcephaly (20%). In the face, the philtrum
is often long but it is infrequently flat as in typical CdLS. In add-
ition, the vermillion border of the upper lip tends to be thin less
frequently. Only one subject has major cardiac defect, none have
diaphragmatic defects and only a minority of individuals have
cutis marmorata (17%), single palmar creases (20%) or restric-
tion of elbow range of motion (4%).
DISCUSSION
Variable clinical severity caused by HDAC8 mutations
Inan ongoing effort tounderstand the phenotypic consequences of
mutations inHDAC8, we screened a broad cohort of subjects with
CdLS or features that overlap the diagnosis and have sought to
identify patients with HDAC8 mutations ascertained independ-
ently of a diagnosis of CdLS. In total, we have identified 38 indi-
viduals with mutations in HDAC8. These range from genomic
copy number abnormalities through single nucleotide substitu-
tions that cause missense mutations. Based on these numbers,
individuals with HDAC8 mutations comprise 4% of patients
ascertained (25 probands of 586 screened). However, the identifi-
cation of HDAC8 mutations by genomic testing in seven indivi-
duals without a diagnosis of CdLS affirms that this phenotype
differs from typical CdLS and may ultimately have wider
ranging features than even the patients reported here. Further-
more, the severity of clinical phenotypes caused by mutations in
HDAC8, especially in females, is heavily influenced by random
X-inactivation. We would suspect that females with unfavorable
Lyonization in the brainwoulddisplay a moreaffectedphenotype,
but additional investigation would be needed to test this model.
HDAC8 mutations in CdLS cause reduced enzymatic
activity
Although we have noted a range of clinical features, genetic and
biochemical analysis of all HDAC8 mutations to date causing
CdLS or overlapping phenotypes predict or demonstrate loss
Table 1. Skewed X-inactivation with HDAC8 mutations
Patient DNA source Gender Allele
1:Allele 2
cDNA allele
expressed
C0007 Blood Female 97:3 N/A
C0084 Blood Female 98:2 N/A
C0146 Blood (3 years
7 months)
Female 16:84 N/A
CDL016P Blood Female 100:0 100% wt
CDL016P Fibroblast Female 0:100 100% mut
CDL179P Blood Male 100 N/A
CDL209P Blood Female 100:0 100% wt
CDL231P Blood Female 0:100 N/A
CDL233P Blood Male 100 N/A
CDL248P Blood Female UTD 100% wt
CDL248P Fibroblast Female UTD 100% mut
CDL279P Blood (infant) Female 59:41 N/A
CDL317P Blood Female 100:0 100% wt
CDL326AS Blood Female 100:0 N/A
CDL326M Blood Female UTD N/A
CDL326P Blood Male 100 N/A
CDL347P Blood Male 100 N/A
CDL423M Blood Female 100:0 N/A
CDL423P Blood Male 100 N/A
CDL426P Blood Male 100 100% mut
CDL603P Blood Female 100:1 100% wt
CDLG13952 Blood (3 years) Female 8:92 N/A
D11-209M Blood Female 2:98 N/A
DECIPHER
268420
Blood Female 100:0 N/A
HD8HC01P Blood (1 year) Female 100:0 N/A
R19E9 Blood Female 95:5 N/A
R19H7 Blood Female 2:98 N/A
R23F4 Blood Female 98:2 N/A
R24E11 Blood Female 3:97 N/A
R34B12 Blood (15
months)
Female 85:15 N/A
R34B12 Blood (5 years) Female 100:0 N/A
R27C10 Blood Female 1:99 N/A
Patient ID, source of DNA, age (in parentheses where relevant) and sex are
indicated. The ratio of the activity is noted for each allele. In the allele ratio
column, ‘UTD’ indicates that skewing cannot be determined due to
homozygosity of the AR microsatellite allele tested. In this column, samples are
shaded to indicate whether they are male (blue), female skewed toward the
mutated allele (red), female skewed toward the normal allele (green), female
skewed toward unknown allele (gray) or unskewed (unshaded). Note that in some
familial cases (CDL326, CDL423), the determination of the wild-type and
mutant alleles is inferred from an affected male family member. nd, not
determined; N/A, not available; wt, wild-type allele; mut, mutated allele.
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of function. Several mutations we have identified result from
microdeletions or microduplications that disrupt the gene and
several result from nonsense substitutions. Furthermore, enzym-
atic assays of all missense mutations demonstrated reduced or
absent activity. This correlates with in silicomapping of the mis-
sense mutations using the known crystal structure that shows
these are often located in or around residues critical for
HDAC8 function. Although the numbers are quite small, there
is a weak trend in males toward a milder phenotype with
higher residual activity of HDAC8. However, a significant
caveat exists for this observation, since this assay was performed
in vitrowith standardized amounts of purified HDAC8, and does
not represent in vivo levels of protein. Unfortunately, we have
cell lines for very few of the affected boys to determine stability
of each mutation in vivo and further studies would be needed to
more clearly correlate genotype and clinical severity.
Complete loss of HDAC8 function appears to be viable in
humans, as evidenced by a male with a partial deletion of
HDAC8 (D11–209P) and another with undetectable levels of
HDAC8 protein in cells (CDL426P). This is supported by the
finding that mice with a targeted null mutation can be viable,
albeit at lower frequencies than wild type (38). This differs
from the survivability seen for loss of other cohesin genes
(39–41) in which homozygous knockouts result in embryonic
lethality. This finding suggests that the endogenous function of
HDAC8 may be at least partially redundant, or that other pro-
teins, such as related deacetylases, may be upregulated to com-
pensate for HDAC8 loss of function.
Overlapping and unique features caused byHDAC8
mutations
Although the facial features certainly overlap those of patients
with typical CdLS caused by NIPBL mutations, there are
notable features in individuals with HDAC8 mutations. Several
of the most distinct likely derive from an abnormality of skull for-
mation. Quite notably, this effect is directly comparable with the
Hdac8 mouse knockout, which demonstrates extreme growth
failure and markedly delayed closure of skull sutures (38). In a
large percentage of individuals with HDAC8 mutations,
delayed, sometimes marked, closure of the anterior fontanelle
has been observed. We hypothesize that this effect represents an
embryonic anomaly that results in delayed development of
midline structures of the face to result in hypertelorism,
Figure2. IndividualswithHDAC8mutations. Facial features of individualswithHDAC8mutations labeledwith corresponding mutation and sex;F, male;C, female.
Photos for individual patients are grouped, with the first image for each containing the type of mutation and sex, and the last image containing the subject identifier.
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Table 2. Clinical feature frequency in individuals with HDAC8 mutations
Category Feature Percent (no. observed/no. assessed) Details
Head Brachycephaly 70% (24/34)
Low anterior hairline 67% (23/34)
Skull Prominent metopic suture (1), open/delayed
fontanelles (13), asymmetry (2)
Eyes Arched eyebrows 88% (30/34)
Synophrys 90% (30/33)
Long eyelashes 45% (14/31)
Hypertelorism 47% (16/34)
Telecanthus 64% (22/34)
Ptosis 18% (6/32)
Myopia 44% (11/25)
Lacrimal duct obstruction 24% (6/25)
Hooding of lids 46% (15/32)
Nose Depressed nasal bridge 45% (15/33)
Anteverted nostrils 76% (26/34)
Long philtrum 57% (19/33)
Featureless philtrum 30% (10/33)
Broad/bulbous nasal tip 66% (22/33)
Mouth Thin upper lip 29% (10/34)
Downturned corners of mouth 57% (19/33)
Palate—high arch 33% (7/21)
Palate—cleft 18% (5/27)
Widely spaced teeth 61% (16/26)
Gap between upper incisors 50% (13/26)
Other teeth (19) Congenital abnormalities (10), oligodontia
(3), fused (4), delayed (6)
Micrognathia/retrognathia 59% (19/32)
Short neck 48% (12/25)
Other facial Facial asymmetry (2), grimacing smile (1),
small low-set ears (5), macrostomia (1),
premature aging (1)
Skin Cutis marmorata 18% (5/27)
Hirsutism 65% (21/32)
Nevus flammeus 58% (17/29)
Other skin Pigmentary mosaicism (6), slow-growing hair
and nails (1)
Hands Small hands 96% (28/29)
Proximally set thumbs 85% (23/27)
Clinodactyly 5th finger 50% (14/28)
Short 5th finger 84% (21/25)
Single Palmar crease 20% (5/24)
Feet Small feet 89% (26/29)
Syndactyly of toes 44% (12/27)
Arms Restriction of elbow movements 4% (1/23)
Other skeletal Atypical/absent patella (2)
Cardiac Cardiac defects Leg asymmetry (5), Short 4/5 metacarpals, 5th
fingers and distal (6), phalanges of thumbs
Genitourinary Genitourinary defects 36% (11/30)
Gastrointestinal GER 44% (13/29) VUR/hydronephrosis (6), renal cysts (2),
dysplasia (2), chronic disease (2),
cryptorchidism or hypoplastic genitalia (5/
8 males) PCOS (2)
Feeding problems in infancy 67% (19/28)
GI anomalies 86% (25/29)
Other gastrointestinal
Otolaryngologic Hearing loss 59% (16/27)
CNS CNS anomalies 22% (6/27)
Seizures 28% (8/28)
Other Hypertonia (3), hypotonia (1), gait apraxia (1)
Cognitive Intellectual disability 100% (30/30) Carrier mothers not carefully evaluated
Behavior, personality (23) Autistic (3), friendly (14), hyperactive (3),
aggressive (3 older), self-injurious (3)
Clinical features are summarized by category. Percent and fractional data are indicated. Single numbers in parentheses indicate the number assessed or noted with the
feature. M, male; F, female; PCOS, polycystic ovarian syndrome; GER, gastroesophageal reflux; CNS, central nervous system; VUR, vesicoureteral reflux.
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telecanthus and/or forehead nevus flammeus. Furthermore,
several additional facial features, including hooding of eyelids
anddental anomalies, aredistinctive in thiscohort.These findings,
in combination with a more well-formed philtrum and upper lip,
suggest that the face may be useful in defining a clinically recog-
nizable subgroup of individuals. While all affected cases demon-
strate some dysmorphic facial features, there is a significant
diversity of facial appearance within the HDAC8-mutated sub-
jects. This diversity may reflect level of mutation load in the em-
bryonic face (in the context of unaffected mothers) or an evolving
phenotype with age. However, it may also provide clues to
domain-specific functions of the protein.
Of note, a family was recently reported by Harakalova et al.
(26), in which affected males demonstrate intellectual disability,
truncal obesity, hypogonadism and distinctive facial features
caused by a splice site mutation in HDAC8. This family does
not demonstrate facial features or a body build of typical
CdLS, suggesting that the mechanism of this mutation may
differ from that for cases of CdLS initially noted with HDAC8
mutations (25). In support of this, our cohort had only three indi-
viduals for whom obesity was a significant feature. However,
several of the boys reported by Harakalova et al. (26) demon-
strate some weak similarity with hooding of the eyelids and
arched eyebrows. In combination with the wide range of pheno-
types seen in our cohort, it is possible that this family represents
another instance of an emerging spectrum of phenotypes caused
byHDAC8mutations. Further analysis of the mutation identified
in this family and the role of HDAC8 in growth and metabolism
will be useful to help further understand these observations.
Updated clinical diagnostic approach for CdLS
Based on genotype–phenotype correlations, we currently recom-
mend the following diagnostic approach for patients with features
suggestive of CdLS due to atypical growth, cognition, facies or
limbs. For those with classical facial features, NIPBL should be
assessed first, preferably in buccal or skin cells as suggested by
Huisman et al. (8). If a multiple cohesin gene panel is not available
and the facial features are atypical, X-inactivation studies may be
useful. In the setting of atypical facies, a wide fontanelle, hooding
of the eyelids and/or heavily skewed X-inactivation studies,
HDAC8 assessment would be increased in priority. For those
with atypical features that include broader fuller less arched eye-
brows or a broader nasal tip, SMC1A, and perhaps SMC3, assess-
ment would be higher priority than HDAC8 (14). If the above
testing is negative, RAD21 should be considered. As exome
sequencing coverage increases, exome-based exon-level copy
number analysis improves, and the cost of exome sequencing
falls, it will become reasonable to consider exome sequencing
as first line testing for this heterogenous disorder.
Unique clinical recommendations for these patients
For patients in whom an HDAC8 mutation is suspected or iden-
tified, we would include a workup similar to patients with a diag-
nosis of classical CdLS (42,43), which typically includes
cardiac, renal and gastroenterologic studies, palate evaluation,
hearing studies, speech, physical and occupational therapy
assessments, molecular studies to confirm a diagnosis, and as-
sessment of platelet levels and immune function. In addition, a
careful maternal family history should be assessed and molecu-
lar testing of all mothers of children for whomHDAC8mutations
have been found should be considered. If a high suspicion of an
HDAC8 mutation exists but none is identified, X-inactivation
studies could help to increase or decrease suspicion of a mutation
in the region.
In conclusion, mutations in HDAC8 comprise 4% of muta-
tions in individuals with features suggestive of CdLS and result
in an atypical clinical phenotype that has elements of overlap
with patients harboring NIPBL mutations. However, in general,
there are several exceptions to the phenotypic similarity that
include wide skull fontanelles, hooded eyelids, a slightly
broader nasal base and a notably pleasant personality. This work
emphasizes the role of acetylation of non-histone targets in
human development and stresses the need for additional studies
to understand the mechanism of cohesin regulation in the
context of human developmental disorders.
MATERIALS ANDMETHODS
Subjects
All individuals in this study were diagnosed by clinical geneti-
cists to have clinical features consistent with or overlapping a
diagnosis of CdLS or were found to have HDAC8 mutations
identified by genome-wide analyses. All subjects and family
members were enrolled in the study under an institutionally
approved protocol of informed consent at The Children’s
Hospital of Philadelphia, the Institut fu¨r Humangenetik
Lu¨beck or the UK (Scotland A) MREC Committee. All probands
ascertained as CdLS were previously screened and found nega-
tive for mutations in NIPBL and SMC1A. Most were previously
Table 3. Comparison of quantitative features between males and females with HDAC8 mutations and classical CdLS
Parameter HDAC8 males HDAC8 females Classical CdLS
Birth weight 21.7 (23 to 20.5, n ¼ 6) 21.6 (23.6 to 0, n ¼ 21) 21.9 (23.0 to 0.0)
Birth length 22.4 (24 to 21, n ¼ 5) 21.9 (24 to +0.5, n ¼ 17) 21.5 (24.3 to +0.7)
Birth head circumference 21.7 (22.8 to 20.5, n ¼ 2) 21.8 (23 to +1.5, n ¼ 12) 22.0 (22.8 to 20.9)
Subsequent weights 22.8 (26.5 to 20.3, n ¼ 7) 21.4 (26.5 to +3.0, n ¼ 22) 24.8 (210.1 to 21.8)
Subsequent heights 22.8 (26.6 to +0.4, n ¼ 7) 22.0 (24.5 to +0.4, n ¼ 22) 24.1 (28.0 to 21.2)
Subsequent head circumference 22.5 (26.6 to 20.4, n ¼ 7) 21.9 (25 to +1, n ¼ 21) 23.8 (25.6 to 21.5)
Growth parameters are noted at the top. Z-scores were calculated using the LMS values from 2000 United States CDC Growth Percentile Data Files (36). Data within
the HDAC8 categories are presented as: (Z-score average, minimum-to-maximum range and the number or individuals with available data). Z-scores for classical
CdLS data are derived from Kline et al. (37) and represents an average of both sexes at birth and 3 years for the mean and 5th–95th percentile range.
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screened for mutations in SMC3, RAD21 and other cohesin
genes. Subjects with HDAC8 mutations found by genome-wide
methods were enrolled following their identification.
Mutation screening
The coding exons and intron–exon boundaries of HDAC8 were
amplified by PCR of genomic DNA and Sanger sequenced.
Primers were designed using ExonPrimer (http://ihg.gsf.de/
ihg/ExonPrimer.html) (44). Primer sequences and PCR condi-
tions (25) are available upon request. Sequencing was performed
using BigDye Terminator v3.1 cycle sequencing and analyzed
on an ABI 3730 (Applied Biosystems, Carlsbad, CA, USA).
Genome-wide copy number analysis
Whole-genome SNP genotyping was performed using Illumina
(San Diego, CA, USA) Infinium HumanHap550 or Omni 1 M
Beadchip or Affymetrix (Fremont, CA, USA) Genome-Wide
Human SNP 6.0 arrays according to the manufacturer’s proto-
cols. Copy number calling was performed using published algo-
rithms (45) and PennCNV (46). Inspection of copy number
variants was performed for Xq13.1 by analyzing allele fre-
quency and log R ratio values using Illumina BeadStudio (ver.
3.1.3) or Affymetrix Chromosome Analysis Suite (version 1.0)
software as described (47). For case R19H7, genome-wide ana-
lysis of DNA copy number aberrations was carried out using the
Roche Nimblegen 3 × 720K whole-genome array (median
probe spacing of 2 kb) according to the manufacturer’s
instructions, modified as follows: 500 ng of genomic DNA
from patient and sex-matched control samples (pool of five
samples) was labeled for 2 h followed by hybridization for
72 h. After washing, slides were scanned using the Roche
MS200 scanner, and analyzed using the software NimbleScan
(Roche Nimblegen). The CGH-segMNT module of NimbleScan
was used for the analysis with a minimum segment length of five
probes and an averaging window of 20 kb.
Exome sequencing
Exome capture and sequencing was performed in several clinic-
ally validated diagnostic labs. Subject HD8HC01P exome se-
quencing and copy number analysis were performed using the
UW CMG CoNIFER pipeline (48).
Reference sequences and HDAC8 conservation analysis
HDAC8 accession numbers used to include NM_018486.2
(mRNA), NP_060956 (RefSeq protein) and Q9By41 (UniProt).
HDAC8 protein sequences for human (AAF73428), Bos taurus
(DAA12953), rat (AAI62023), mouse (CAM17598), Danio
rerio (NP_998596), Xenopus laevis (NP_001085711), Xenopus
tropicalis deduced from mRNA BC161282, Drosophila melano-
gaster (AAC61494) and for Saccharomyces cerevisiae HDAC8-
like proteins, HOS1 (Q12214) and RPD3 (AAT92832) were
aligned by the ClustalW method (49) using MacVector software
(Accelrys Corp, San Diego, CA, USA).
Mapping mutations to HDAC8 structure
Identified HDAC8 mutations were mapped onto the crystal
structure data of human HDAC8-substrate complex (PDB acces-
sion code 2V5W) (27) to visualize location with respect to the
enzyme active site using Cn3D (50) and PyMol (51) software.
Recombinant HDAC8 purification from E. coli
Missense humanHDAC8mutations were introduced into a previ-
ously described HDAC8–6His-pET20b construct (30) using
QuikChange site-directed mutagenesis (Agilent Genomics,
Santa Clara, CA, USA). Oligonucleotide sequences are available
upon request. Recombinant wild-type HDAC8 and mutants I19S,
H42P, H71Y, P91L, G117E, C153F, H180R, A188 T, D233G,
D237Y, DK239-Y240N, I243N, G304R, T311M, G320R and
H334R were expressed in BL21(DE3) E. coli cells and purified
according to a previously published procedure (30), with minor
modifications. Briefly, 50 ml cultures (LB media supplemented
with 100 mg/l ampicillin) were grown overnight and used to in-
oculate 1 l flasks (minimal media supplemented with 100 mg/l
ampicillin). Typically, 2–6 l were expressed for each mutant.
Cells were grown at 378C until OD600 0.5, at which point the
temperature was lowered to 188C. After 30 min, cells were
induced by the addition of isopropyl b-D-thiogalactopyranoside
(0.4 mM final concentration) and zinc chloride (100 mM final con-
centration), and grown overnight at 188C. The cells were pelleted
by centrifugation and kept at 2808C until purification. After
thawing, cells were resuspended in  30 ml of lysis buffer
(50 mM Tris (pH 8.0), 500 mM KCl, 5% glycerol, 3 mM
b-mercaptoethanol (BME) and 115 mM phenylmethanesulfonyl
fluoride), and lysed by sonication on ice. Cell debris was pelleted
by centrifugation and the supernatant was purified by affinity
chromatography (Talon resin, Clontech Labs) using an imidazole
gradient. After loading the cell-free extract in buffer A (50 mM
Tris (pH 8.0), 500 mM KCl, 5% glycerol, 3 mM BME), the
column was washed with 4% buffer B (50 mM Tris (pH 8.0),
500 mM KCl, 250 mM imidazole, 5% glycerol, 3 mM BME) and
the protein was eluted with a 4–80% linear gradient of buffer
B. Fractions containing the protein were pooled and concentrated
to  500 ml by ultrafiltration. The protein was then dialyzed at
48C against buffer C (50 mM Tris (pH 8.0), 150 mM KCl, 5% gly-
cerol, 1 mM dithiothreitol). Protein concentrations were deter-
mined from the absorbance using a calculated extinction
coefficient: 50 240 M21 cm21 for the wild type and all the
mutants except H71Y (51 520 M21cm21), C153F (50 180
M
21 cm21), D237Y (51 520 M21 cm21) and DK239-Y240N
(48 960 M21 cm21) (52). The H42P mutant did not express a
soluble protein under these conditions.
HDAC8 activity assays
Enyzmatic activity of purified proteins was measured using the
commercially available Fluor-de-Lys HDAC8 deacetylase sub-
strate (BML-KI178-0005) and Developer II (BML-KI176-1250)
from Enzo Life Sciences. In this assay, deacetylation of the tetra-
peptide substrate (acetyl)-L-Arg-L-His-L-Lys(1-acetyl)-L-Lys(1-
acetyl)-aminomethylcoumarin allows a protease developer to
cleave the amide bond linking the C-terminal aminomethylcou-
marin to the peptide backbone, which results in a fluorescence
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shift. All assays were run at 258C in assay buffer (25 mM Tris
(pH ¼ 8.2), 137 mM NaCl, 2.7 mM KCl, 1 mM MgCl2) and con-
tained 150 mM substrate with the following enzyme concentra-
tions: 0.5 mM (wild type, P91L, H334R), 1.0 mM (A188 T),
1.5 mM (I19S, I243N, D233G, D237Y, G320R), 2.5 mM (H71Y,
G117E, H180R, DK239-Y240N, G304R, T311M) or 3 mM
(C153F) enzyme. After 30 min, reactions were quenched by the
addition of the HDAC8 inhibitor M344 (Sigma-Aldrich,
100 mM) and Developer II. The fluorescence of both remaining
substrate and formed product was measured using a Fluoroskan
II plate reader (excitation ¼ 355 nm, emission ¼ 460 nm).
Product concentration was calculated from raw data using stand-
ard curves for substrate and product (Aminomethylcoumarin,
Enzo Life Sciences), with the total concentration of substrate
and product kept at 150 mM (before dilution with the developer so-
lution). All assays were performed in triplicate.
Tissue culture
Lymphoblastoid cell lines (LCLs) were cultured in RPMI 1640
supplemented to 20% FBS and 2% 20 mM L-glutamine,
100 units/ml penicillin and 100 mg/ml streptomycin at 378C in
5% CO2. HeLa cells were cultured at 378C and 5% CO2 in
DMEM supplemented to 10% FBS. Nonsense-mediated decay
was inhibited using 1 mg/ml cycloheximide (Sigma-Aldrich,
St. Louis, MO, USA) in culture media for 6 h prior to harvesting
RNA.
Assessment of X-inactivation
X chromosome inactivation (XCI) was determined by evaluating
the methylationstatus of theCAG microsatellite locusat the 5′ end
of the AR gene as previously described with modifications
(35,53). Briefly, genomic DNA was isolated from peripheral
blood or cell lines and for each sample, two reaction digests
were performed. In one reaction, 1 mg of DNA was digested in
25 ml with the methylation-sensitive restriction enzyme HpaII
(New England Biolabs), to cut the active unmethylated allele. In
the other reaction, DNA was incubated in enzyme digest buffer
without enzyme. After a 16 h incubation at 378C, digestion was
terminated by incubation at 658C for 20 min. From each reaction,
2 ml was then amplified by PCR with primers flanking the poly-
morphic androgen-receptor CAG repeat as described (35);
forward 5′-CTGTGAAGGTTGCTGTTCCTCAT-3′; reverse
5′-FAM-TCCAGAATCTGTTCCAGAGCGTGC-3′). ABI3730
Genetic Analyzer and GeneMapper V4.0 software (Applied
Biosystems) was used for genotyping analysis. Percent
X-inactivation was calculated by dividing the ratio of the allele
peak volumes in the HpaII-treated by the ratio of the allele peak
volumes in the untreated sample. We considered alleles separated
by more than two trinucleotide repeats as informative (54) and
used a cutoff of .80:20% for skewed XCI and .95:5% for ex-
tremely skewed XCI.
SUPPLEMENTARYMATERIAL
Supplementary Material is available at HMG online.
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